» Articles » PMID: 22187299

Frequent Germ-line Mutations of the MEN1, CASR, and HRPT2/CDC73 Genes in Young Patients with Clinically Non-familial Primary Hyperparathyroidism

Overview
Journal Horm Cancer
Date 2011 Dec 22
PMID 22187299
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Familial primary hyperparathyroidism (FPHPT) may occur due to an underlying germ-line mutation in the MEN1, CASR, or HRPT2/CDC73 genes. The disease may be undiagnosed in the absence of a history suggestive of FHPT. Young PHPT patients (≤45 years of age) are more likely to harbor occult FPHPT. A total of 1,161 (136 were ≤45 years of age) PHPT patients underwent parathyroidectomy from 2001 to 2009. Thirty-four patients declined participation. Sixteen patients were diagnosed in the clinical routine with FPHPT (11 MEN1, four MEN2A, and one HPT-JT) and were not included in the genetic analysis. Eighty-six young (≤45 years of age) patients with clinically non-syndromic PHPT underwent genetic analysis. Sanger sequencing of all coding regions of the MEN1, CASR, and the HRPT2/CDC73 genes was performed. Eight of 86 (9.3%) young patients with clinically non-familial PHPT displayed deleterious germ-line mutations in the susceptibility genes (4 MEN1, 3 CASR, and 1 HRPT2/CDC73). There was one insertion, one deletion, two nonsense, and four missense mutations, all predicted to be highly damaging to protein function and absent in 3,244 control chromosomes. Germ-line mutations in known susceptibility genes within young patients with PHPT, including those diagnosed in the clinical routine, was 24/102 (23.5%; 15 MEN1, four RET, three CASR, and two HRPT2/CDC73). We demonstrate that germ-line inactivating mutations in susceptibility genes are common in young patients with clinically non-familial PHPT. Thus, enhanced use of genetic analysis may be warranted in clinically non-familial young PHPT patients.

Citing Articles

c.1155-3A>G is a pathogenic variant that causes aberrant splicing, disrupted parafibromin expression, and hyperparathyroidism-jaw tumor syndrome.

Needleman L, Chun N, Sitaraman S, Tan M, Sellmeyer D, Kebebew E JBMR Plus. 2024; 9(1):ziae149.

PMID: 39677927 PMC: 11646312. DOI: 10.1093/jbmrpl/ziae149.


The Role of Demographic and Clinical Factors in Germline Mutation Testing for Patients with Primary Hyperparathyroidism.

Hangge P, Dream S, Yen T, Doffek K, Stachowiak S, Shaker J Ann Surg Oncol. 2024; 31(6):3964-3971.

PMID: 38459417 DOI: 10.1245/s10434-024-15104-3.


Targeting GABARAPL1/HIF-2a axis to induce tumor cell apoptosis in nasopharyngeal carcinoma.

Huang X, Zhou L, Chen J, Zhang S Iran J Basic Med Sci. 2024; 27(2):157-164.

PMID: 38234672 PMC: 10790296. DOI: 10.22038/IJBMS.2023.72952.15863.


Genetic testing for familial hyperparathyroidism: clinical-genetic profile in a Mediterranean cohort.

Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto M, Barcons S, Guirao X Front Endocrinol (Lausanne). 2023; 14:1244361.

PMID: 37810884 PMC: 10558207. DOI: 10.3389/fendo.2023.1244361.


Clinical Factors Predicting Multiple Endocrine Neoplasia Type 1 and Type 4 in Patients with Neuroendocrine Tumors.

Faggiano A, Fazzalari B, Mikovic N, Russo F, Zamponi V, Mazzilli R Genes (Basel). 2023; 14(9).

PMID: 37761922 PMC: 10531237. DOI: 10.3390/genes14091782.


References
1.
Pollak M, Brown E, Chou Y, Hebert S, Marx S, Steinmann B . Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993; 75(7):1297-303. DOI: 10.1016/0092-8674(93)90617-y. View

2.
Skogseid B, Rastad J, Oberg K . Multiple endocrine neoplasia type 1. Clinical features and screening. Endocrinol Metab Clin North Am. 1994; 23(1):1-18. View

3.
Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S . MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer. 2010; 17(3):771-83. DOI: 10.1677/ERC-10-0028. View

4.
Eastell R, Arnold A, Brandi M, Brown E, DAmour P, Hanley D . Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94(2):340-50. DOI: 10.1210/jc.2008-1758. View

5.
Guarnieri V, Canaff L, Yun F, Scillitani A, Battista C, Muscarella L . Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J Clin Endocrinol Metab. 2010; 95(4):1819-29. DOI: 10.1210/jc.2008-2430. View